The appointments will add to the well-diversified experience that currently exists on the PPL board
Piramal Pharma announced the addition of Peter Stevenson, Nathalie Leitch and Sridhar Gorthi to the board of directors. These new appointments, which come ahead of the planned de-merger of PPL from Piramal Enterprises (PEL), will assist in maintaining high governance for the new listed corporate entity.
The appointments will add to the well-diversified experience that currently exists on the PPL board. Led by Chairperson Nandini Piramal and Piramal Global Pharma CEO Peter DeYoung, the Piramal Pharma board also includes leaders such as S Ramadorai, Neeraj Bhardwaj, Jairaj Purandare and Vivek Valsaraj.
Stevenson brings in-depth knowledge in contract manufacturing, business operations, supply chain management and operating in a complex regulatory environment. Gorthi is an authority in corporate law, M&A and private equity. His experience spans manufacturing, pharmaceuticals, insurance, banking and financial services, technology, telecom and media. Leitch is a subject matter expert in pharmaceuticals and the US generics industry, with domain experience in creative product strategies and formulations.
Nandini Piramal, Executive Director, Piramal Enterprises and Chairperson of Piramal Pharma board commented, “We welcome the new members to the PPL board. Having a diversified, experienced global board will strengthen our governance, as we vertically de-merge from PEL and become a listed entity. The wisdom and knowledge the new members bring will not only enhance the overall expertise of the board but also provide crucial insights to the businesses, as we scale up our global presence by pursuing both organic and inorganic growth.”
